These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 31131593)

  • 1. Fosfomycin in the pediatric setting: Evidence and potential indications.
    Baquero-Artigao F; Del Rosal Rabes T
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):55-61. PubMed ID: 31131593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fosfomycin in antimicrobial stewardship programs.
    Múñez Rubio E; Ramos Martínez A; Fernández Cruz A
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):62-66. PubMed ID: 31131594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fosfomycin--its significance for treatment of diseases due to multidrug-resistant bacteria].
    Stock I
    Med Monatsschr Pharm; 2015 Jan; 38(1):4-11. PubMed ID: 26349119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial.
    del Río A; Gasch O; Moreno A; Peña C; Cuquet J; Soy D; Mestres CA; Suárez C; Pare JC; Tubau F; Garcia de la Mària C; Marco F; Carratalà J; Gatell JM; Gudiol F; Miró JM;
    Clin Infect Dis; 2014 Oct; 59(8):1105-12. PubMed ID: 25048851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New perspectives for reassessing fosfomycin: applicability in current clinical practice.
    Candel FJ; Matesanz David M; Barberán J
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):1-7. PubMed ID: 31131586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous fosfomycin for the treatment of hospitalized patients with serious infections.
    Shorr AF; Pogue JM; Mohr JF
    Expert Rev Anti Infect Ther; 2017 Oct; 15(10):935-945. PubMed ID: 28901793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fosfomycin: use beyond urinary tract and gastrointestinal infections.
    Falagas ME; Giannopoulou KP; Kokolakis GN; Rafailidis PI
    Clin Infect Dis; 2008 Apr; 46(7):1069-77. PubMed ID: 18444827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists.
    Reffert JL; Smith WJ
    Pharmacotherapy; 2014 Aug; 34(8):845-57. PubMed ID: 24782335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
    Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
    Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients.
    Jones RN
    Am J Med; 1996 Jun; 100(6A):3S-12S. PubMed ID: 8678095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral and intravenous fosfomycin in complicated urinary tract infections.
    López-Montesinos I; Horcajada JP
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):37-44. PubMed ID: 31131591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fosfomycin: past, present and future].
    Baylan O
    Mikrobiyol Bul; 2010 Apr; 44(2):311-21. PubMed ID: 20549968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of fosfomycin in the treatment of bacterial infections.
    Hutzler R; Fernandes V; Muñoz D; Rozentraub A
    Chemotherapy; 1977; 23 Suppl 1():358-64. PubMed ID: 832537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Profile and susceptibility to antibiotics in urinary tract infections in children and newborns from 2012 to 2013: Data from 1879 urine cultures].
    Marzouk M; Ferjani A; Haj Ali M; Boukadida J
    Arch Pediatr; 2015 May; 22(5):505-9. PubMed ID: 25842196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fosfomycin: Resurgence of an old companion.
    Sastry S; Doi Y
    J Infect Chemother; 2016 May; 22(5):273-80. PubMed ID: 26923259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidrug-resistant bacteria in hospitalized children: a 5-year multicenter study.
    Raymond J; Nordmann P; Doit C; Vu Thien H; Guibert M; Ferroni A; Aujard Y
    Pediatrics; 2007 Apr; 119(4):e798-803. PubMed ID: 17403822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The revival of fosfomycin.
    Michalopoulos AS; Livaditis IG; Gougoutas V
    Int J Infect Dis; 2011 Nov; 15(11):e732-9. PubMed ID: 21945848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linezolid in children: recent patents and advances.
    Velissariou IM
    Recent Pat Antiinfect Drug Discov; 2007 Jan; 2(1):73-7. PubMed ID: 18221164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of fosfomycin tromethamine against extended spectrum beta-lactamase producing urinary tract bacteria.
    Khan IU; Mirza IA; Ikram A; Ali S; Hussain A; Ghafoor T
    J Coll Physicians Surg Pak; 2014 Dec; 24(12):914-7. PubMed ID: 25523727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial.
    Rosso-Fernández C; Sojo-Dorado J; Barriga A; Lavín-Alconero L; Palacios Z; López-Hernández I; Merino V; Camean M; Pascual A; Rodríguez-Baño J;
    BMJ Open; 2015 Mar; 5(3):e007363. PubMed ID: 25829373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.